KIORA PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
KIORA PHARMACEUTICALS, INC. (KPRX) reported Payments to Acquire Debt Securities, Available-for-sale of $9.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $9.12M, a 100.21% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $8.18M, a 77.05% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $35.63M.
- KIORA PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $9.12M 10-Q · filed 2026-08-07 | $9.12M derived: sum of 3 quarters · filed 2026-08-07 | $9.12M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-05-08 | $0.00 derived: sum of 3 quarters · filed 2026-05-08 | $4.56M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $4.56M derived: sum of 3 quarters · filed 2026-08-07 | $8.18M 10-K · filed 2026-03-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.56M derived: sum of 2 quarters · filed 2026-08-07 | $8.18M 10-Q · filed 2025-11-07 | $14.71M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $4.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $8.18M 10-Q · filed 2026-08-07 | $14.71M derived: sum of 3 quarters · filed 2026-08-07 | $22.52M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $3.62M 10-Q · filed 2026-05-08 | $10.16M derived: sum of 2 quarters · filed 2026-05-08 | $17.96M derived: sum of 3 quarters · filed 2026-05-08 | $39.25M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $14.34M derived: sum of 2 quarters · filed 2026-03-25 | $35.63M derived: sum of 3 quarters · filed 2026-03-25 | $35.63M 10-K · filed 2026-03-25 |
| 2024-09-30 | $7.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $29.09M derived: sum of 2 quarters · filed 2025-11-07 | $29.09M 10-Q · filed 2025-11-07 | $29.09M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $21.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $21.29M 10-Q · filed 2025-08-08 | $21.29M derived: sum of 3 quarters · filed 2025-08-08 | $21.29M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-05-09 | $0.00 derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 10-K · filed 2025-03-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |